SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Kura Oncology reported Q1 2026 results with $5.8M in KOMZIFTI product…

Kura Oncology, Inc. · 8-K filed May 12, 2026 at 16:10 ET

At the news

NEUTRALIMPACT 5/10

8-K filed May 12, 2026 at 16:10 ET

Kura Oncology reported Q1 2026 results with $5.8M in KOMZIFTI product revenue (first full commercial quarter), beating consensus revenue estimates. However, the net loss widened to $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025, driven by increased R&D and SG&A costs for the commercial launch and clinical trials. The company maintains a strong cash position of $580.8M plus $180M in anticipated collaboration payments, funding operations into 2028.

  • Q1 2026 net product revenue of $5.8M from KOMZIFTI, first full commercial quarter
  • 85 new patient starts and 157 total prescriptions in Q1 2026
  • Net loss of $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025
  • Cash and investments of $580.8M as of March 31, 2026, down from $667.2M at year-end 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access